This study investigates pancreatic cancer. It evaluates the use of surgery to remove cancer tissue, followed by treatment with camrelizumab and personalized cancer mRNA vaccines.
The study focuses on assessing the safety and effectiveness of these treatments in patients with pancreatic cancer. This study evaluates how well these interventions work together.
- Who can participate: Adults aged 18 and older with resectable pancreatic tumors may participate. Key factors include a confirmed diagnosis of ductal pancreatic adenocarcinoma, an ECOG performance status of 0 or 1, and an estimated life expectancy of at least 12 weeks.
- Study details: Participants will undergo surgery to remove cancer tissue, followed by treatment with camrelizumab and personalized mRNA vaccines.
How understandable was the trial content above?
Hard to understand
Easy to understand